Methods: We performed a secondary analysis of self-identified African American and white subjects with asthma enrolled in clinical trials conducted by the National Heart, Lung, and Blood Institute-sponsored Asthma Clinical Research Network and AsthmaNet. Demographics, clinical characteristics, and sputum cytology after sputum induction were examined. We used a sputum eosinophil 2% cut point to define subjects with either an eosinophilic (> _2%) or noneosinophilic (<2%) inflammatory phenotype. Results: Among 1018 participants, African American subjects (n 5 264) had a lower FEV 1 percent predicted (80% vs 85%, P < .01), greater total IgE levels (197 vs 120 IU/mL, P <.01), and a greater proportion with uncontrolled asthma (43% vs 28%, P < .01) compared with white subjects (n 5 754). There were 922 subjects in the ICS1 group (248 African American and 674 white subjects) and 298 subjects in the ICS2 group (49 African American and 249 white subjects). Eosinophilic airway inflammation was not significantly different between African American and white subjects in either group (percentage with eosinophilic phenotype: ICS1 group: 19% vs 16%, P 5 .28; ICS2 group: 39% vs 35%, P 5.65; respectively). However, when adjusted for confounding factors, African American subjects were more likely to exhibit eosinophilic airway inflammation than white subjects in the ICS1 group (odds ratio, 1.58; 95% CI, 1.01-2.48; P 5 .046) but not in the ICS2 group (P 5 .984). Conclusion: African American subjects exhibit greater eosinophilic airway inflammation, which might explain the greater asthma burden in this population. (J Allergy Clin Immunol 2017;140:257-65.)
Key words: Asthma, race, eosinophil, airway inflammation, African American, body mass index, corticosteroid, induced sputum, clinical trial African American subjects have a higher prevalence of asthma than white subjects and a greater burden of morbidity and mortality, with rates of asthma-related emergency department visits, hospitalizations, and death being approximately 2 to 3 times the rates observed in white subjects. 1, 2 Many factors, including asthma severity, differences in access to health care, and environmental exposures, have been implicated as causes of race-related variations in asthma burden. [3] [4] [5] [6] [7] [8] Studies that have controlled for these factors have still found higher asthmarelated emergency department visits, hospitalizations, and death from asthma among African American subjects. [9] [10] [11] Results of some studies suggest that African American subjects can have reduced responsiveness to some asthma therapies, including inhaled corticosteroids (ICSs), compared with white subjects, suggesting biological differences in asthma between these groups. [12] [13] [14] [15] The basis for race-related differences in asthma burden and treatment responsiveness is not well understood.
Airway inflammation is a key cornerstone of asthma pathogenesis and is mediated by numerous inflammatory cells that infiltrate the airways, including eosinophils, neutrophils, type 2 lymphocytes, basophils, and mast cells. 16 By counting these inflammatory cells in induced sputum, airway inflammation in asthmatic patients has been characterized as either eosinophilic (> _2% eosinophils) or noneosinophilic (<2% eosinophils). [17] [18] [19] Emerging evidence suggests that differences in airway inflammatory phenotype can affect response to asthma therapies. [20] [21] [22] In one study subjects with noneosinophilic asthma had an impaired response to treatment with oral and high-dose ICSs compared with those with eosinophilic asthma. 20 Relatively few African American patients with asthma (21/158 patients) were included in this study, and therefore it remains unclear whether differences in airway inflammation could explain, at least in part, the observed race-related disparities in asthma burden. 20 These considerations led us to ask the following question: Are there differences in the prevalence of eosinophilic versus noneosinophilic airway inflammatory phenotypes in African American versus white patients with asthma? Because ICS use can improve asthma control and modify the observed airway inflammatory phenotype, we compared the clinical characteristics and airway inflammation phenotypes in African American and white subjects separately in patients receiving (ICS1) and off (ICS2) ICS treatment.
METHODS

Study population
The study population consisted of self-reported African American or white patients with asthma enrolled in 10 clinical trials conducted by the National Heart, Lung, and Blood Institute-sponsored Asthma Clinical Research Network (ACRN) and AsthmaNet (see Fig E1 and Table E1 in this article's Online Repository at www.jacionline.org) that included at least 1 sputum induction as part of the study protocol. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The data were collected as part of the clinical trials that had been reviewed and approved by institutional review boards at all participating ACRN and AsthmaNet centers, and all subjects provided written informed consent. The University of Illinois Institutional Review Board deemed the secondary analyses in this report to be exempt from human subject review.
All subjects were aged 12 years or older; met the criteria for mild or moderate persistent asthma, as defined by the National Asthma Education and Prevention Program Guidelines for the Diagnosis and Management of Asthma; were current nonsmokers with a lifetime history of smoking no greater than 10 pack years; and had not smoked within the past 12 months (see Table E1 ). 33 In addition, all subjects had to have either (1) a positive methacholine challenge result with a provocative concentration for a 20% decrease in FEV 1 of less than or equal to 16 mg/mL in ICS1 subjects or less than or equal to 12 mg/mL in ICS2 subjects or (2) a postbronchodilator increase in FEV 1 of 12% or greater. Sputum eosinophils were the chosen inflammatory marker for this study because evidence supports that differences in airway inflammatory phenotype affect asthma exacerbations and response to asthma therapies. 20, 21 Sputum induction data and corresponding clinical data were only included when ICS use or nonuse was known and standardized as part of the study protocols. Subjects in the ICS1 group were receiving ICSs (fluticasone equivalent dose range, 80-400 mg/d) for at least 4 weeks before sputum assessment. Those in the ICS2 group had not been treated with ICSs for at least 6 weeks before the time of sputum assessment. In the ICS2 group patients using a leukotrienemodifying agent in the 4 weeks before sputum induction or clarithromycin [34] [35] [36] Only unique subjects were included within the ICS1 or ICS2 groups. Subjects meeting the criteria for both groups either at different time points in a study or participating in a different study were included in the analyses.
The following measures were collected by trained research staff using standardized procedures: self-reported race (African American or white subjects), anthropometrics (age, sex, and body mass index [BMI]), atopic status (> _1 positive allergy test result), prebronchodilator FEV 1 , asthma symptom control (Asthma Control Questionnaire [ACQ] or Asthma Control Test [ACT] score, depending on the trial protocol), maximum bronchodilator responsiveness (percentage change in FEV 1 after 4 puffs of albuterol), total blood eosinophil counts, and total serum IgE levels. 37, 38 We defined uncontrolled asthma as a score of 1.5 or greater by using the ACQ or 19 or less by using the ACT. ACQ or ACT data were not collected in 2 studies (Salmeterol Off Corticosteroids [SOCS] and SMOG), and maximum bronchodilator responsiveness data were not collected in 2 studies (SOCS and Salmeterol and Leukotriene Modifiers vs. Salmeterol and ICS Treatment [SLIMSIT] ). Blood eosinophil counts and total serum IgE levels were used as secondary markers of inflammation because recent studies have shown an association with asthma severity. 39, 40 Blood eosinophil counts are also a promising biomarker for eosinophilic airway burden. 41 Blood eosinophil and total serum IgE data were not collected in 4 studies (SMOG, Measuring Inhaled Corticosteroid Efficacy [MICE] , SOCS, and Vitamin D in Asthma [VIDA] ). Blood eosinophil data were available but not used in 1 study (SLIMSIT) because subjects were not receiving standardized treatment at the time of blood collection.
Two induced sputum samples
We examined a subgroup of participants who underwent at least 2 sputum inductions (8 studies; see Fig E1) because a previous study found that sputum eosinophilia is intermittent. 20 Two sputum samples from 2 different time points when the participant was taking the same treatment regimen for at least 4 weeks in the ICS1 group and at least 6 weeks in the ICS2 group were analyzed for sputum eosinophilia. Eosinophilia of 2% or greater occurring on 1 or both sputum inductions defined eosinophilic airway inflammation.
Sputum induction and processing
Sputum was collected by using methods validated for consistency and quality control, as previously described. 42, 43 Briefly, subjects had spirometry performed before and 10 minutes after 360 mg of inhaled albuterol to ensure postbronchodilator FEV 1 of greater than 50% of predicted value. A 12-minute sputum induction was then performed, and cell differentials (eosinophils, neutrophils, macrophages, epithelial cells, and lymphocytes) were calculated as the percentage of cells in the whole sputum expectorate. Sputum samples with 80% or greater squamous epithelial cells were not included in the analysis. The other cell types in the sputum were calculated as the percentage of nonsquamous cells. The presence or absence of eosinophilic inflammation was determined by using a 2% cutoff based on published reference values for eosinophils in induced sputum from healthy subjects; subjects with 2% or greater sputum eosinophils were classified as having eosinophilic airway inflammation, and subjects with less than 2% sputum eosinophils were classified as having noneosinophilic airway inflammation. 17, 18 The presence of neutrophilic inflammation was determined by using a 61% cutoff based on published reference values for neutrophils in induced sputum. 44 Subjects with greater than 61% sputum neutrophils were classified as having neutrophilic airway inflammation, and subjects with 2% or greater sputum eosinophils and greater than 61% sputum neutrophils were classified as having mixed eosinophilic/neutrophilic phenotype.
Analyses
Continuous variables are presented as means and SDs or medians and interquartile ranges, as appropriate. Categorical variables are reported by using frequencies and percentages. Differences between groups were assessed by using 2-sample t tests, Wilcoxon rank sum tests, Fisher exact tests, or x 2 tests, as appropriate. In the subgroup of participants who underwent a second sputum induction, we calculated the intraclass correlation coefficient to assess the within-individual reliability of percentage eosinophils in separate sputum inductions in unique subjects. We used multivariable logistic regression models to assess the adjusted association between race and eosinophilic airway inflammation after accounting for potential confounders separately in the ICS1 and ICS2 groups. The variables for the multivariable logistic regression model were selected if they were significantly different between African American and white subjects. To avoid collinearity in the regression models, we did not include total serum IgE levels (related to atopy) and sputum neutrophilia (related to BMI).
Analyses were performed with SAS (version 9.3; SAS Institute, Cary, NC) and Systat (version 11; Systat, San Jose, Calif) statistical software. A 2-tailed P value of less than .05 was used to denote statistically significant differences.
RESULTS
Subjects' characteristics
Of the 1018 subjects, 264 (26%) self-identified as African American. Compared with white subjects (n 5 754 [74%]), African American subjects were significantly older, had a higher BMI, had a lower FEV 1 percent predicted, were more likely to have uncontrolled asthma, and had higher total IgE level (Table I ). In the large majority of both African American and white subjects, the age at asthma onset was before age 40 years (Table I) .
ICS1 subjects
Of 922 ICS1 subjects, 248 (27%) were African American (Table II) . African American subjects were older and less atopic; had a higher BMI, lower FEV 1 percent predicted, and higher total serum IgE levels; and were more likely to have uncontrolled asthma compared with white subjects. There was no significant difference in age at asthma onset, total blood eosinophil counts, or percentage of sputum eosinophils/neutrophils in African American and white subjects (Table II) . Only 17% of ICS1 subjects had eosinophilic airway inflammation. There were no significant differences between the African American and white subgroups (19% vs 16%, P 5 .28; Fig 1) , even when stratified by age, age of asthma onset, atopy, and presence or absence of uncontrolled asthma (see Table E2 in this article's Online Repository at www.jacionline.org). When stratified by BMI, the proportion with eosinophilic airway inflammation was similar among African American and white subjects, except for those with a BMI of 30 kg/m 2 or greater (see Table E2 ). In the subgroup with a BMI of 30 kg/m 2 or greater, African American subjects were more likely to have eosinophilic airway inflammation than white subjects (16% vs 8%). Of those subjects with eosinophilic airway inflammation, there was no difference in the percentage of sputum eosinophils in African American versus white subjects (6.8% vs 5.9%, P 5 .95, respectively). African American subjects with eosinophilic airway inflammation were twice as likely to have a mixed granulocytic airway inflammation (> _2% eosinophils and >61% neutrophils) compared with white subjects (7% vs 3%, P 5 .02). In noneosinophilic subjects almost three quarters had neutrophilic airway inflammation (>61% neutrophils). African American subjects were less likely to exhibit this airway inflammatory pattern (71% vs 75%, P 5 .02).
ICS2 subjects
Of ICS2 subjects, 16% (n 5 49) were African American (Table III) . African American subjects had a higher BMI. As in J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 1 the ICS1 group, there was no difference in the percentage of sputum eosinophils/neutrophils in African American and white subjects (Table III) . Only 36% of ICS2 subjects had eosinophilic airway inflammation, with no significant difference between the African American and white subgroups (39% vs 35%, P 5 .65; Fig 1) , even when stratified by BMI, age, age of asthma onset, atopy, and uncontrolled asthma (see Table E3 in this article's Online Repository at www.jacionline.org). In contrast to ICS1 subjects ICS2 eosinophilic subjects showed a trend toward a lower percentage of sputum eosinophils in African American subjects compared with white subjects (5.4% vs 9.4%, P 5 .07, respectively). African American subjects with eosinophilic airway inflammation were 4 times as likely to have mixed granulocytic airway inflammation compared with white subjects (14% vs 3%, P 5 .003). African American subjects with noneosinophilic airway inflammation were twice as likely to exhibit neutrophilic inflammation (>61% neutrophils; 35% vs 17%, P 5 .004).
Multivariable logistic regression
A multivariable logistic regression analysis was performed in the ICS1 and ICS2 subgroups to investigate whether race was associated with eosinophilic airway inflammation after accounting for potential confounders (age, sex, atopic status, BMI, FEV 1 Values above represent means 6 SDs, unless otherwise indicated. The total number of patients in Tables II and III do not equal the total number of unique patients shown in Table I because 203 (20%) patients met the criteria to be included (at different times) for both the ICS1 and ICS2 groups. Patients were treated with ICSs for at least 4 weeks to be in the ICS1 group. IQR, Interquartile range. *One or more positive skin test results. Uncontrolled asthma 5 ACT score < _19 or ACQ score > _1.5. àAsthma control data are available for 775 subjects: 222 African American subjects and 553 white subjects. §Blood eosinophil data are available for 378 subjects: 85 African American subjects and 293 white subjects. kTotal serum IgE data are available for 466 subjects: 104 African American subjects and 362 white subjects.
percent predicted, and uncontrolled asthma; see Table E4 in this article's Online Repository at www.jacionline.org). Interestingly, race was associated with eosinophilic airway inflammation in the ICS1 group only. African American subjects had a 58% greater odds of eosinophilic airway inflammation than white subjects (odds ratio, 1.58; 95% CI, 1.01-2.48; n 5 757; P 5 .046; Fig 2) . There were no race-related differences in eosinophilic airway inflammation in the ICS2 stratum, although there were fewer subjects in this stratum, and the CIs were wide.
Analyses of 2 induced sputum samples
Four hundred seventy-seven (47%) subjects had at least 2 induced sputum samples that were included in the analysis. The interval between the sputum inductions varied from 2 to 53 weeks (see Fig E2 in this article' s Online Repository at www.jacionline. org). African American subjects who had at least 2 induced sputum samples were younger (ICS2 group only) and had a higher BMI and lower FEV 1 percent predicted (ICS1 group only, see Tables E5 and E6 in this article's Online Repository at www.jacionline.org). When compared with subjects with 1 induced sputum sample, subjects with 2 induced sputum samples were older and had a higher BMI, lower FEV 1 percent predicted, and greater bronchodilator reversibility (see Table E7 in this article's Online Repository at www.jacionline.org). When results from 2 induced sputum samples were used, the percentage of subjects (ICS1 and ICS2 groups) with eosinophilic airway inflammation increased, supporting the intermittent nature of eosinophilia that occurs in the asthmatic airway (Fig 3) . There were no significant race-related differences in the proportion of subjects with eosinophilic airway inflammation when results of 2 induced sputum samples from the same subject were used (within the ICS1 and ICS2 groups: P 5.29 and .78, respectively; Fig 3) . The induced sputum pattern of inflammation within a subject remained eosinophilic or noneosinophilic in 80.1% (339/423) of unique subjects when sputum induction was repeated; the intraclass correlation coefficient for percentage sputum eosinophils between 2 induced sputum samples was 0.31 in ICS1 group (fair agreement) and 0.68 in the ICS2 group (moderate agreement).
DISCUSSION
The principal findings from this study were (1) only a minority of subjects with mild or moderate persistent asthma had an eosinophilic sputum airway inflammatory phenotype and (2) there are race-related differences in eosinophilic airway inflammation in asthmatic patients treated with ICSs.
The current report significantly contributes to the current body of literature on the influence of race on airway inflammatory patterns in asthmatic patients. A previous study, which included only small numbers of African American subjects (25 patients), suggested potential variations in airway inflammation based on race. 45 In this previous study African American subjects with asthma had a greater number of sputum neutrophils, but the analysis did not take into account ICS use. 45 The current study includes a 10-fold higher number of African American patients with asthma (n 5 264) and examined eosinophilic and noneosinophilic airway inflammation separately in patients treated with or without ICSs.
We did not observe race-related differences in eosinophilic and noneosinophilic airway inflammation until we accounted for potential confounders. After accounting for baseline differences in age, sex, atopic status, BMI, FEV 1 percent predicted, and uncontrolled asthma, we observed an increased odds of eosinophilic airway inflammation in African American subjects taking ICSs. Significant race differences in neutrophilic and mixed granulocytic airway inflammation were also found. Neutrophilic airway inflammation is commonly seen in patients with severe disease. 46 In our population of patients with mild-to-moderate asthma, it was frequently seen both in African American and white subjects in the ICS1 group, likely because of ICS use. However, in the ICS2 group African American subjects were twice as likely to have neutrophilic inflammation, which might identify a group of patients that could be less responsive to ICS treatment. 47 Mixed granulocytic airway inflammation is associated with poorer asthma control, greater asthma symptoms and health care use, and lower lung function. Our findings of higher numbers of African American subjects with this inflammatory pattern in both the ICS1 and ICS2 groups suggests a mechanism that can account for more severe and difficult-to-control asthma in African American subjects. Further cluster analyses in African American patients with asthma might identify whether the mixed granulocytic inflammatory pattern identifies patients with severe asthma, as has been reported previously in a predominantly white population. 48 We identified a number of race-related differences in clinical characteristics. African American subjects had lower lung function (FEV 1 percent predicted) and higher BMI and total serum IgE levels, and they were more likely to have uncontrolled asthma. These findings are consistent with previous reports indicating lower lung function and increased total serum IgE levels are associated with a greater burden of asthma among African American compared with white subjects. Our study suggests that differences in eosinophilic airway inflammation can contribute to race-related differences in asthma burden. This increased risk of eosinophilic airway inflammation in African American subjects receiving ICSs might be due to higher rates of corticosteroid insensitivity and reduced cellular sensitivity to corticosteroids in African American patients with asthma.
14,50,51 However, the biologic mechanisms for steroid insensitivity are unclear and can include a decreased number of steroid receptors, reduced steroid receptor binding, increased nuclear transcription factor levels, or other pharmacogenomic effects. 15, [52] [53] [54] Although differential adherence might account for differences in patterns of airway inflammation, a previous study examining race effects on treatment failures in ACRN trials showed similar medication adherence in African American and white subjects (87.5% vs 91%, respectively). 13 Therefore differential adherence likely does not affect the findings of this current study. In this analysis we found that BMI among African American subjects was about 6 kg/m 2 higher than among white subjects (ICS1 and ICS2 groups combined). Some studies suggest that obesity is associated with more difficult-to-control asthma and a poor response to asthma treatment or corticosteroid insensitivity. 52, 55 Whether the combination of African American race and obesity leads to greater corticosteroid insensitivity is yet to be determined. Obesity (BMI > _30 kg/m 2 ) in this study was found to be associated with an eosinophilic phenotype only in African American subjects taking ICSs. This might indicate a race interaction in airway inflammation, although larger studies that adjust for the higher rates of obesity in this particular subgroup of asthmatic patients are needed to confirm our finding. Because obesity is associated with worse asthma control, efforts directed at obesity prevention and weight loss might help reduce race-related asthma disparities. [56] [57] [58] The major strengths of this study include the large number of African American and white subjects with asthma enrolled in Values above represent means 6 SDs, unless otherwise indicated. The total number of subjects in Tables II and III do not equal the total number of unique subjects shown in Table I because 203 (20%) subjects met the criteria to be included (at different times) for both the ICS1 and ICS2 groups. Odds ratio estimates and 95% CIs for eosinophilic airway inflammation (> _2% eosinophils) in African American versus white subjects stratified by ICS status. Estimated odds ratios with 95% CIs are shown for eosinophilic airway inflammation after adjusting for age, sex, atopy, BMI, FEV 1 percent predicted, and uncontrolled asthma. In the ICS1 group African American subjects were significantly more likely to have eosinophilic airway inflammation (P 5 .046) compared with white subjects. In the ICS2 group no significant race-related differences in eosinophilic airway inflammation were observed, although the CIs were wide and the number of subjects in the ICS2 stratum was approximately 25% of the number of subjects in the ICS1 stratum. Depending on the protocol in the parent clinical trials, some subjects contributed to the ICS1 and ICS2 strata at different points in the trial (n 5 89 subjects); a total of 852 unique subjects contributed to the analyses. See Table E4 for adjusted odds ratios for other covariates in the analyses.
these clinical trials conducted across the United States and the analysis of data from multiple studies using standardized protocols and quality controls for sputum induction and cytology measurements.
However, there are a number of potential limitations to the study. Notably, our study was conducted among clinical trial participants with mild or moderate persistent asthma. It is not known whether our findings are generalizable to patients with intermittent or severe persistent asthma. Results of studies in clinical trial participants might not apply to all patients with asthma because only a minority of these patients are eligible and enroll in clinical trials. Moreover, we used self-reported race in this study; further studies using genetic ancestry markers to classify patients' race are recommended. Use of genetic ancestry markers will provide the opportunity to examine the extent to which the airway inflammatory phenotype varies with the percentage of African ancestry (rather than a dichotomous ''race'' variable). 59 We assessed 2 broad phenotypes of airway inflammation: eosinophilic and noneosinophilic. We recognize that other inflammatory phenotypes exist: neutrophilic and paucigranulocytic. The relationship of these inflammatory phenotypes with a clinical phenotype is not clearly defined and is an area for further research.
Furthermore, our analysis relied mostly on a single assessment of airway inflammation using induced sputum. Although induced sputum is a direct and noninvasive measure of airway inflammation, other measures, including blood eosinophil counts, exhaled nitric oxide levels, and total serum IgE levels, have been associated with greater asthma severity, yet have not consistently been shown to predict ICS treatment responsiveness to the same degree as sputum eosinophils have. [60] [61] [62] Blood eosinophil counts and total serum IgE levels were measured in a subset of patients in this analysis. No difference was found in blood eosinophil counts, although African American subjects had significantly higher total serum IgE levels compared with white subjects. Larger studies examining additional measures of airway inflammation, such as blood eosinophil counts, activated airway eosinophil counts, exhaled nitric oxide levels, and total serum IgE levels, should be pursued to fully address airway inflammatory differences that might exist in African American and white patients with asthma.
The analyses we conducted in the subset of patients with 2 induced sputum samples demonstrated no significant race-related differences in the proportion of patients with eosinophilic (or noneosinophilic) asthma. These analyses included sputum samples with highly variable time periods between the 2 induced sputum samples (up to 53 weeks, depending on the study). Additionally, subjects included might not be representative of the entire sample because we reported differences in the clinical characteristics of subjects with 1 versus 2 induced sputum samples. These differences are likely due to variations in eligibility criteria used in the different study protocols (some of which included 2 induced sputum samples).
The findings from our study have important clinical implications. In both African American and white subjects with mild-to-moderate asthma, we found that noneosinophilic airway inflammation was the predominant pattern. Patients with noneosinophilic airway inflammation might not benefit from treatment intensification that focuses on targeting eosinophils, such as ICSs. Other treatments, such as the addition of b-agonists and/or antimuscarinic agents, should be considered. 20, 21 In a recent post hoc analysis, African American subjects without atopic inflammation (history of eczema and increased blood eosinophil counts and total serum IgE levels) had a better response to adding a long-acting b-agonist compared with increasing the dose of the ICS or adding a leukotriene modifier. 63 Another important finding from this study is that African American subjects taking ICSs were more likely to have eosinophilic airway inflammation. There are multiple factors Frequency of eosinophilic airway inflammation (> _2% eosinophils on one or both sputum inductions) in subjects with 2 sputum samples. A, Sputum inflammatory cell profile assessed by the first versus 2 sputum samples in African American (black bars; n 5 99) and white (white bars; n 5 266) subjects in the ICS1 subgroup with 2 sputum samples analyzed. B, Sputum inflammatory cell profile assessed by the first versus 2 sputum samples in African American (black bars; n 5 22) and white (white bars; n 5 90) subjects in the ICS2 subgroup with 2 sputum samples analyzed. Overall, there were no significant differences by race observed in each ICS stratum.
that might account for this novel finding, including greater disease severity, uncontrolled asthma, obesity, and glucocorticoid resistance, in African American subjects in the ICS1 group. 14,50,51 Although we did not see a race difference in those not taking ICSs, this could be due to the small sample size in the ICS2 group. Additional studies in African American adults need to be performed to determine whether race and atopic status affect the response to therapy in those on and off ICSs. There is an ongoing AsthmaNet study evaluating the most efficacious add-on treatment options in African American patients with asthma, which will begin to address our knowledge gaps in this field. 22 In summary, in our study of more than 1000 patients with asthma (a quarter of whom were African American), we found evidence of worse asthma impairment (lower lung function, higher total serum IgE levels, and worse symptom control) among African American compared with white subjects and a greater risk of eosinophilic airway inflammation in African American subjects receiving ICS treatment. We conclude that differences in eosinophilic airway inflammatory phenotype in the context of ICS use might contribute to the greater burden of asthma in African American compared with white subjects. Additional studies are needed to address the mechanisms underlying this novel finding, particularly the role of ICSs in this patient population.
We acknowledge the study participants, the ACRN and AsthmaNet clinical research coordinators, and the data coordinating center.
Clinical implications: African American patients with asthma carry a greater disease burden than white patients. Racerelated differences in eosinophilic airway inflammation might contribute to the disparities in adults with asthma on ICSs.
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Weeks ICS-Group SMOG (Non-smoker group, ICS and LTRA groups) 4 sputum inductions (SI) over 22 weeks, 2 SIs at week 10 and 24 were used for analysis. Subjects were on placebo for at least 6 weeks prior to SI.
SOCS (Placebo and LABA only groups)
7 SIs over 28 weeks, 2 consecutive SIs at week 14 and 22 were used for analysis. Subjects were on placebo or LABA only for at least 6 weeks prior to SI.
IMPACT (Placebo group)
2 SIs over 53 weeks, beginning at least 10 weeks post-treatment ICS+ Group SOCS (ICS group) 7 SIs over 28 weeks, 2 consecutive SIs at week 6 and 8 were used for analysis. Subjects were on ICS for at least 4 weeks prior to SI. . Clinical studies and 2 consecutive sputum inductions used in analyses of sputum inflammatory phenotypes. The blue and white circles indicate the sputum samples used for analysis. The week 18 and 32 sputum induction for the SMOG nonsmoker group was not included because subjects were receiving treatment. The week 8 sputum induction for the SOCS steroid-untreated group was not included because it occurred less than 6 weeks after discontinuation of ICS treatment. Weeks 24 and 28 in the SOCS steroid-untreated group and weeks 14, 22, and 22 in the SOCS steroid-treated group were not used because only the first 2 consecutive sputum samples were analyzed. Because of the crossover design in Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC), the second sputum sample used for analysis was taken from either week 18, 34, or 50, which was based on when the subject was taking the same ICS dose because they were on when the first sputum induction occurred (week 4). The week 18 and 36 sputum induction for SLIMSIT was not included because of treatment differences. Values above represent means 6 SDs, unless otherwise indicated. *Age at asthma onset data are available for 364 subjects: 99 African American subjects and 265 white subjects. Uncontrolled asthma 5 ACT score < _19 or ACQ score > _1. 5 . àAsthma control data are available for 335 subjects: 93 African American subjects and 242 white subjects. Studies from which participants were drawn 1-10k 1,3,5-10k <.01
Values above represent means 6 SDs, unless otherwise indicated. IS, Induced sputum. *Age at asthma onset data are available for 592 subjects with 1 IS and 418 subjects with 2 IS. One or more positive skin test results. àUncontrolled asthma 5 ACT score < _19 or ACQ score > _1. 5. §Asthma control data are available for 500 subjects with 1 IS sample and 370 subjects with 2 IS samples. 
